Assessing abuse liability during drug development: changing standards and expectations - PubMed (original) (raw)
Review
Assessing abuse liability during drug development: changing standards and expectations
K A Schoedel et al. Clin Pharmacol Ther. 2008 Apr.
Abstract
As public health concerns have changed, regulatory expectations for assessing abuse liability of new central nervous system (CNS) drugs have increased. All CNS-active drugs with any properties indicating stimulant, depressant, hallucinogenic, or mood-elevating effects will require an evaluation of abuse liability. Abuse liability assessment involves the collection, analysis, and interpretation of data on chemistry and tampering, animal behavioral pharmacology, clinical trial adverse events (AEs), diversion and overdose, and potentially reinforcing (subjective) effects in recreational drug users.
Similar articles
- Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
Abanades S, Farré M, Barral D, Torrens M, Closas N, Langohr K, Pastor A, de la Torre R. Abanades S, et al. J Clin Psychopharmacol. 2007 Dec;27(6):625-38. doi: 10.1097/jcp.0b013e31815a2542. J Clin Psychopharmacol. 2007. PMID: 18004131 Clinical Trial. - Barcelona meeting on clinical testing of drug abuse liability: consensus statement and recommendations.
[No authors listed] [No authors listed] Br J Addict. 1991 Dec;86(12):1527-8. Br J Addict. 1991. PMID: 1786481 Review. No abstract available. - Relationship between reinforcing properties and sensory/motor toxicity of CNS depressants; implications for the assessment of abuse liability.
Brady JV, Lukas SE, Hienz RD. Brady JV, et al. NIDA Res Monogr. 1983 Apr;43:196-202. NIDA Res Monogr. 1983. PMID: 6410252 No abstract available. - CNS stimulants and the look-alike drugs.
Lake CR, Quirk RS. Lake CR, et al. Psychiatr Clin North Am. 1984 Dec;7(4):689-701. Psychiatr Clin North Am. 1984. PMID: 6151645
Cited by
- A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans.
Dunn KE, Bergeria CL, Huhn AS, Strain EC. Dunn KE, et al. Front Psychiatry. 2019 Sep 26;10:704. doi: 10.3389/fpsyt.2019.00704. eCollection 2019. Front Psychiatry. 2019. PMID: 31616329 Free PMC article. - Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM. Harris SC, et al. J Clin Pharmacol. 2014 Apr;54(4):468-77. doi: 10.1002/jcph.235. Epub 2013 Dec 11. J Clin Pharmacol. 2014. PMID: 24243216 Free PMC article. Clinical Trial. - Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women.
Fox HC, Sinha R. Fox HC, et al. Harv Rev Psychiatry. 2009;17(2):103-19. doi: 10.1080/10673220902899680. Harv Rev Psychiatry. 2009. PMID: 19373619 Free PMC article. - Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
Webster L, Henningfield J, Buchhalter AR, Siddhanti S, Lu L, Odinecs A, Di Fonzo CJ, Eldon MA. Webster L, et al. Pain Med. 2018 Feb 1;19(2):307-318. doi: 10.1093/pm/pnw344. Pain Med. 2018. PMID: 28340145 Free PMC article. Clinical Trial. - Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.
Smith SM, Jones JK, Katz NP, Roland CL, Setnik B, Trudeau JJ, Wright S, Burke LB, Comer SD, Dart RC, Dionne R, Haddox JD, Jaffe JH, Kopecky EA, Martell BA, Montoya ID, Stanton M, Wasan AD, Turk DC, Dworkin RH. Smith SM, et al. J Pain. 2017 Nov;18(11):1287-1294. doi: 10.1016/j.jpain.2017.03.015. Epub 2017 May 4. J Pain. 2017. PMID: 28479207 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials